Clinical‐scale production of cGMP compliant CD3/CD19 cell‐depleted NK cells in the evolution of NK cell immunotherapy at a single institution

• Published in: Transfusion (Philadelphia, Pa.) Vol. 58; no. 6; pp. 1458 - 1467
• Main Authors: Williams, Shelly M., Sumstad, Darin, Kadidlo, Diane, Curtsinger, Julie, Luo, Xianghua, Miller, Jeffrey S., McKenna, David H.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.06.2018
• Subjects: Adoptive immunotherapy; Antigens, CD19; Apheresis; Automation; CD19 antigen; CD3 antigen; CD3 Complex; CD56 antigen; Cell activation; Cell Culture Techniques - methods; Clinical trials; Contamination; Cyclic GMP; Cytokines; Cytokines - pharmacology; Cytotoxicity; Cytotoxicity, Immunologic - drug effects; Depletion; Evolution; Humans; Immunomagnetic Separation; Immunotherapy; Immunotherapy - methods; Interleukins; Killer Cells, Natural - cytology; Killer Cells, Natural - drug effects; Leukapheresis; Leukocytes (mononuclear); Lymphocyte Depletion - methods; Lymphocytes; Lymphocytes B; Lymphocytes T; Manufacturing; Medical research; Microspheres; Monocytes; Nanoparticles; Natural killer cells; Purification; Recovery; Toxicity; Viability

BACKGROUND Allogeneic natural killer (NK) cell adoptive immunotherapy is a growing therapeutic option for patients. Clinical‐scale production of NK cells using immunomagnetic selection complies with current good manufacturing practices (cGMPs) and allows for closed‐system, automated purification. We...